Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K.
McCourt CK, Wei Z, Kalinsky K, Gray R, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Force J, Pakanati A, Tricoli JV, Conley BA, Arteaga C, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. McCourt CK, et al. Among authors: kalinsky k. Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-24-3431. Online ahead of print. Clin Cancer Res. 2025. PMID: 40577532
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.
Bardia A, Rugo HS, Sedrak MS, Loibl S, Tolaney SM, Punie K, Hurvitz SA, Kalinsky KM, Cortés J, O'Shaughnessy JA, Dieras V, Piccart-Gebhart MJ, Dasgupta A, Kaushik A, Lai C, Shi L, Brufsky A. Bardia A, et al. Among authors: kalinsky km. JCO Oncol Pract. 2025 Jun 25:OP2400806. doi: 10.1200/OP-24-00806. Online ahead of print. JCO Oncol Pract. 2025. PMID: 40561376
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
Gambardella V, Accordino MK, Bedard PL, Cervantes A, Hamilton E, Italiano A, Kalinsky K, Krop IE, Oliveira M, Saura C, Schmid P, Turner NC, Varga A, Fernandez-Saranillo A, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman JL, Juric D, Jhaveri KL. Gambardella V, et al. Among authors: kalinsky k. ESMO Open. 2025 Jun 12;10(7):105303. doi: 10.1016/j.esmoop.2025.105303. Online ahead of print. ESMO Open. 2025. PMID: 40513140 Free article.
Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States.
Nanda R, Yam C, Spring L, Bhave MA, Ntalla I, Valdez T, Stwalley B, Liang C, Wu WH, Sjekloca N, Sadetsky N, Lai C, Kalinsky K. Nanda R, et al. Among authors: kalinsky k. ESMO Open. 2025 Jun;10(6):105308. doi: 10.1016/j.esmoop.2025.105308. Epub 2025 Jun 5. ESMO Open. 2025. PMID: 40479864 Free PMC article.
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.
García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J. García-Estévez L, et al. Among authors: kalinsky k. ESMO Open. 2025 Jun;10(6):105294. doi: 10.1016/j.esmoop.2025.105294. Epub 2025 Jun 2. ESMO Open. 2025. PMID: 40460679 Free PMC article. Clinical Trial.
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.
Jhaveri KL, Im SA, Saura C, Loibl S, Kalinsky K, Schmid P, Loi S, Thanopoulou E, Shankar N, Jin Y, Stout TJ, Clark TD, Song C, Juric D, Turner NC. Jhaveri KL, et al. Among authors: kalinsky k. N Engl J Med. 2025 May 31. doi: 10.1056/NEJMoa2501796. Online ahead of print. N Engl J Med. 2025. PMID: 40454641
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. Bidard FC, et al. Among authors: kalinsky k. N Engl J Med. 2025 Jun 1. doi: 10.1056/NEJMoa2502929. Online ahead of print. N Engl J Med. 2025. PMID: 40454637
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.
Jhaveri K, Anders CK, Bardia A, Bhave M, Chien AJ, Krop I, Traina TA, Abdou Y, Basho R, Conlin AK, Esteva FJ, Fox KR, Gadi V, Kaufman PA, Litvak A, Ma CX, Mamounas EP, McArthur H, McCann K, Mitri Z, Shatsky R, Telli M, Torres MA, Kalinsky K. Jhaveri K, et al. Among authors: kalinsky k. Clin Breast Cancer. 2025 Apr 8:S1526-8209(25)00098-9. doi: 10.1016/j.clbc.2025.04.007. Online ahead of print. Clin Breast Cancer. 2025. PMID: 40340127
MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer.
Chi JJ, Xie P, Cheng MH, Zhu Y, Cui X, Watson J, Zeng L, Uddin A, Nguyen H, Li L, Moremen K, Reedy A, Wyatt M, Marcus A, Dai M, Paulos CM, Cristofanilli M, Gradishar WJ, Zhao S, Kalinsky K, Hung MC, Bahar I, Zhang B, Wan Y. Chi JJ, et al. Among authors: kalinsky k. Nat Commun. 2025 Apr 15;16(1):3552. doi: 10.1038/s41467-025-58524-9. Nat Commun. 2025. PMID: 40229283 Free PMC article.
179 results